Core Viewpoint - The company has reported a significant increase in litigation and arbitration cases since August 27, 2025, with a total of 53 new cases involving a monetary amount of 15.423 million yuan, which represents 23.20% of the latest audited net assets [1] Summary by Categories Litigation and Arbitration Cases - The company and its subsidiaries have faced a total of 53 new litigation and arbitration cases since August 27, 2025 [1] - The total amount involved in these cases is 15.423 million yuan [1] - The company is the plaintiff in cases amounting to 5.1766 million yuan, while it is the defendant or respondent in cases totaling 10.2438 million yuan, and it is involved as a third party in cases amounting to 0.0026 million yuan [1] Financial Impact - The total amount of litigation and arbitration cases represents 23.20% of the company's most recent audited net assets [1] - The ongoing nature of these cases introduces uncertainty regarding their impact on the company's current and future profits [1]

Group 1 - Three companies have been temporarily suspended from trading: *ST Zhengping, Shenyang Chemical, and Delixi Shares [1] - One company has resumed trading: *ST Mingjia [1]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、关于非独立董事辞职的情况 日海智能科技股份有限公司（以下简称"公司"、"日海智能"）于 2025 年 9 月 29 日收到曹海霞女士递交的书面辞职报告。曹海霞女士因工作调动原因，申 请辞去第六届董事会副董事长、董事及董事会专门委员会相关职务。曹海霞女士 辞职后不再担任公司其他职务。根据《公司法》《公司章程》及有关法律、法规 的规定，曹海霞女士的辞职申请自送达董事会之日起生效。曹海霞女士辞去董事 职务不会导致公司董事会人数低于法定最低人数，不会影响公司董事会正常运作。 证券代码：002313 证券简称：日海智能 公告编号：2025-065 日海智能科技股份有限公司 关于公司非独立董事辞职及补选的公告 二、关于补选非独立董事的情况 特此公告。 日海智能科技股份有限公司 董事会 截至本公告披露日，曹海霞女士未直接或间接持有公司股份，不存在应当履 行而未履行的承诺事项。公司董事会对曹海霞女士担任前述职务期间的辛勤工作 表示衷心的感谢！ 2025年10月9日 为保证公司董事会的正常运作，根据《中华人民共和国公司法》《 ...

关于公司职工代表监事辞职的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 证券代码：002313 证券简称：日海智能 公告编号：2025-067 日海智能科技股份有限公司 日海智能科技股份有限公司（以下简称"公司"、"日海智能"）近日收到监 事会成员王本西先生递交的书面辞职报告。王本西先生因个人原因，申请辞去第 六届监事会职工代表监事职务，辞职后不再担任公司任何职务。 王本西先生的辞职将导致公司监事会成员低于法定最低人数，根据《深圳证 券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》和《公司章 程》等规定，其辞职需在公司完成监事补选后生效。在尚未选举产生新任监事之 前，王本西先生仍将继续履行监事职责。公司将按照相关规定尽快完成监事的补 选工作或依法取消监事会设置。 王本西先生在任职期间勤勉尽责，为公司规范运作与发展发挥了积极作用。 公司监事会对王本西先生为公司发展所作的贡献表示衷心感谢！ 特此公告。 日海智能科技股份有限公司 监事会 2025年10月9日 ...

证券代码：002313 证券简称：日海智能 公告编号：2025-066 日海智能科技股份有限公司 关于召开2025年第三次临时股东大会的通知 （四）会议召开的日期、时间： 1、现场会议时间：2025年10月24日14:30 2、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的时间为2025年10月24日 9:15-9:25，9:30-11:30和13:00-15:00； 通过深圳证券交易所互联网投票系统投票的时间为2025年10月24日上午9:15 至下午3:00期间的任意时间。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 （一）股东大会届次：2025年第三次临时股东大会 （二）股东大会的召集人：公司董事会。公司第六届董事会第二十三次会议 以6票同意、0票反对、0票弃权的表决结果审议通过了《关于召开2025年第三次 临时股东大会的通知》，同意召开本次股东大会。 （三）会议召开的合法、合规性：公司第六届董事会第二十三次会议于2025 年9月30日召开，会议审议通过了《关于召开2025年第三次临时股东大会的通知》。 本次股东大会 ...

证券代码：002313 证券简称：日海智能 公告编号：2025-064 日海智能科技股份有限公司 第六届董事会第二十三次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 2025年9月30日，日海智能科技股份有限公司（以下简称"公司"、"日海智 能"）第六届董事会在深圳市南山区大新路198号马家龙创新大厦B栋17层公司会 议室举行了第二十三次会议。由于事出紧急，会议通知等会议资料于2025年9月 29日以专人送达或电子邮件的方式送达各位董事。会议召集人已在本次会议上就 紧急召开本次会议的情况进行了说明。本次会议以现场表决结合通讯表决的方式 召开。本次会议应到董事6名，实到董事6名，其中，季翔、薛健、黄海明、赵广 宇、刘江平以通讯表决方式参加。会议由董事长肖建波先生召集并主持。本次会 议召开符合《中华人民共和国公司法》等法律、行政法规、规范性文件和《公司 章程》的有关规定。与会董事以记名投票方式通过以下议案： 一、审议通过《关于补选非独立董事的议案》 表决结果：赞成6票；反对0票；弃权0票。本议案需提交股东大会审议。 鉴于曹海霞女士辞去第六届董事会 ...

Group 1 - The core point of the news is that Wang Benxi has resigned from his position as the employee representative supervisor of the sixth supervisory board of Rihai Intelligent due to personal reasons, and he will no longer hold any position in the company [1] - As of the latest report, Rihai Intelligent has a market capitalization of 4.1 billion yuan [3] - For the first half of 2025, Rihai Intelligent's revenue composition is entirely from AI Internet of Things, accounting for 100.0% [2]

Core Insights - The article discusses the growth and production statistics of China's mobile communication base station equipment, highlighting a 7.8% year-on-year increase in the production of RF modules in May 2025 [1] - Cumulative production from January to May 2025 reached 1.799 million RF modules, reflecting a 3.1% increase compared to the same period in the previous year [1] Industry Overview - The report by Zhiyan Consulting provides insights into the market trends and forecasts for the Chinese communication equipment industry from 2025 to 2031 [1] - The data indicates a positive growth trajectory for the mobile communication base station equipment sector, suggesting potential investment opportunities [1] Company Insights - Listed companies in the communication equipment sector include ZTE Corporation, Datang Telecom Technology, Xinke Mobile, Fenghuo Communication, Shenglu Tongxin, *ST Rihai, and Chaoxun Communication [1] - These companies are positioned to benefit from the increasing demand for mobile communication infrastructure as indicated by the production growth statistics [1]

Group 1 - Qianyu Medical's shareholder QM5 LIMITED plans to transfer approximately 6.6693 million shares, accounting for 2% of the company's total share capital [1] - Guizhou Platinum Industry intends to raise no more than 1.291 billion yuan for technological innovation platform construction, industrial transformation, and working capital [1] - Guangdong Construction has won a bid for the Guangzhou Financial City East District project with a contract value of 1.924 billion yuan [1] Group 2 - Sanfu New Science plans to repurchase shares with a total amount not less than 10 million yuan and not exceeding 15 million yuan [3] - Baiyun Mountain's subsidiary has entered the II phase of clinical trials for children's Xiao Chai Hu granules, aimed at treating pediatric gastrointestinal colds [4] - Lepu Medical has signed a strategic cooperation agreement with Hanhai Information for market promotion and operation rights in mainland China [5] Group 3 - Daotong Technology plans to transfer 46% of its stake in Saifang Technology for a total consideration of 109 million yuan [7] - Rizhao Port's shareholder Shandong Energy Group intends to reduce its stake by up to 3% [8] - Saiwei Electronics reports that the National Integrated Circuit Fund has reduced its stake by 6.3481 million shares, representing 0.87% of the total share capital [10] Group 4 - Changji Logistics proposes a cash dividend of 0.31 yuan per share for the 2025 interim period [11] - Xuelong Group's shareholder plans to reduce its stake by up to 1.95% [13] - Lianxiang Co. plans to reduce its stake by a total of 3.74% [15] Group 5 - Yingfeite's actual controller plans to reduce its stake by up to 2.82% [16] - Baolong Technology's director plans to reduce his stake by up to 0.11% [17] - China Electric Research's shareholder plans to transfer 2% of the company's shares through an inquiry transfer [18] Group 6 - Oriental Pearl plans to participate in establishing an investment fund with a total fundraising scale of 714 million yuan [19] - Tianqin Equipment's shareholder plans to reduce its stake by up to 1% [21] - Crystal Optoelectronics' shareholder plans to reduce its stake by up to 0.99% [22] Group 7 - Changchun Technology expects a net profit increase of 131.39% to 145.38% for the first three quarters of 2025 [22] - Jinhai Tong's shareholder plans to reduce its stake by up to 1% [24] - Zhongdian Electric's shareholder plans to reduce its stake by up to 3% [26] Group 8 - Zhixiang Jintai has signed exclusive cooperation agreements for two monoclonal antibody injections [27] - Chuangli Group's director plans to reduce his stake by up to 0.7% [28] - Henghui Security's shareholders plan to reduce their stake by a total of 2.34% [29] Group 9 - Tianci Materials' subsidiary has signed a supply cooperation agreement for no less than 800,000 tons of electrolyte products [29] - Tianci Materials has submitted an application for H-share listing on the Hong Kong Stock Exchange [30] - Zhongke Haixun has signed a strategic cooperation agreement with Beibu Gulf Port Group [30] Group 10 - China CNR has elected Sun Yongcai as the chairman of the board [31] - Baiwei Storage plans to issue H-shares and list on the Hong Kong Stock Exchange [32] - Shengxin Lithium Energy plans to acquire a 21% stake in Qicheng Mining for 1.456 billion yuan [33] Group 11 - Zhongjing Electronics plans to raise no more than 700 million yuan for various projects [35] - Dingxin Communications clarifies that its technology authorization from Pingtouge is unrelated to AI intelligent reasoning chips [37] - Rihai Intelligent's major shareholder plans to reduce its stake by up to 2.77% [38] Group 12 - Rihai Optical's actual controller plans to reduce his stake by up to 3% [39] - Xilong Science's actual controllers plan to reduce their stake by a total of 3% [40] - Honggong Technology plans to sign a project contract with a maximum investment of 450 million yuan [41] Group 13 - Mankang Pharmaceutical has signed a strategic cooperation agreement with Nanjing Haijing Pharmaceutical [42] - Mankang Pharmaceutical plans to raise no more than 1.033 billion yuan through a private placement [42] - Kaidi Co.'s shareholder plans to reduce its stake by up to 38,030 shares [43] Group 14 - Hesheng Co. has launched a stock option and restricted stock incentive plan totaling 3.6 million shares [44] - ST Yigou's shareholder plans to reduce its stake by up to 2.85% [46] - Jinziham's subsidiary plans to invest up to 300 million yuan in Zhongzheng Microelectronics [49]

Core Insights - The article discusses the increasing trend of antimetabolite drugs in China, highlighting the growth in the number of brands and sales volume in recent years [1][5][11] Antimetabolite Drug Industry Definition and Classification - Antimetabolite drugs interfere with normal cellular metabolism to inhibit cell growth and proliferation, primarily used in cancer treatment [4][6] - These drugs are classified into five categories based on their target mechanisms, including thymidylate synthase inhibitors and dihydrofolate reductase inhibitors [2][6] Current Development Status of Antimetabolite Drugs - The number of antimetabolite drug brands in China has increased to 121 in 2024, with a projected rise to 130 by the first quarter of 2025 [5] - The primary product in the market is capecitabine tablets, which accounted for 51.55% of the market share in 2024, with sales of 41,478 million tablets [5][9] Sales and Market Share of Antimetabolite Drugs - In 2024, the sales volume of capecitabine tablets was 41,478 million tablets, while methotrexate tablets and tegafur capsules had sales of 15,343 million tablets and 15,566 million capsules, respectively [5] - By the first quarter of 2025, capecitabine sales were 11,409 million tablets, maintaining a market share of 54.99% [5] Industry Chain of Antimetabolite Drugs - The upstream of the antimetabolite drug industry includes raw materials like methotrexate and fluorouracil, while the midstream focuses on drug development and production [6][8] - The downstream consists of sales and distribution channels, primarily through medical institutions and pharmacies [6] Competitive Landscape of the Antimetabolite Drug Industry - Major companies in the antimetabolite drug market include Qilu Pharmaceutical, Jiangsu Hengrui Medicine, and Shanghai Pharmaceutical, with Qilu holding a market share of 40.67% in 2024 [8][9] - Sales figures for Qilu Pharmaceutical in 2024 included 22,315 million capecitabine tablets and 10,415 million tegafur capsules [8] Development Trends in the Antimetabolite Drug Industry - The demand for antimetabolite drugs is expected to grow due to an aging population and rising chronic disease rates [11] - The industry is characterized by continuous innovation supported by advancements in biotechnology and molecular biology [11]